Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024.
Merdrignac L, Laniece Delaunay C, Verdasca N, Vega-Piris L, O'Donnell J, Sève N, Trobajo-Sanmartín C, Buda S, Hooiveld M, Rodrigues AP, Túri G, Latorre-Margalef N, Mlinarić I, Lazar M, Maurel M, Castrillejo D, Bennett C, Rameix-Welti MA, Martínez-Baz I, Dürrwald R, Meijer A, Melo A, Oroszi B, Hagey TS, Kurečić Filipović S, Dijkstra F, Gomez V, Bacci S, Kaczmarek M, Kissling E; VEBIS Primary Care Vaccine Effectiveness Group. Merdrignac L, et al. Among authors: laniece delaunay c. Influenza Other Respir Viruses. 2024 Nov;18(11):e70009. doi: 10.1111/irv.70009. Influenza Other Respir Viruses. 2024. PMID: 39523781 Free PMC article.
Corrigendum to "Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: results from the VEBIS primary care test-negative design study, September 2023-January 2024" [Vaccine 42(19) (2024)].
Laniece Delaunay C, Melo A, Maurel M, Mazagatos C, Goerlitz L, O'Donnell J, Oroszi B, Sève N, Paula Rodrigues A, Martínez-Baz I, Meijer A, Mlinarić I, Latorre-Margalef N, Lazăr M, Pérez-Gimeno G, Dürrwald R, Bennett C, Túri G, Rameix-Welti MA, Guiomar R, Castilla J, Hooiveld M, Kurečić Filipović S, Samuelsson Hagey T, Dijkstra F, Borges V, Ramos Marín V, Bacci S, Kaczmarek M, Kissling E; European primary care VE group. Laniece Delaunay C, et al. Vaccine. 2024 Oct 3;42(23):126089. doi: 10.1016/j.vaccine.2024.06.056. Epub 2024 Jul 8. Vaccine. 2024. PMID: 38971666 Free PMC article. No abstract available.
COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans.
Laniece Delaunay C, Mazagatos C, Martínez-Baz I, Túri G, Goerlitz L, Domegan L, Meijer A, Rodrigues AP, Sève N, Ilic M, Latorre-Margalef N, Lazar M, Maurel M, Melo A, Andreu Ivorra B, Casado I, Horváth JK, Buda S, Bennett C, de Lange M, Guiomar R, Enouf V, Mlinaric I, Samuelsson Hagey T, Dinu S, Rumayor M, Castilla J, Oroszi B, Dürrwald R, O'Donnell J, Hooiveld M, Gomez V, Falchi A, Kurecic Filipovic S, Dillner L, Popescu R, Bacci S, Kaczmarek M, Kissling E; VEBIS Primary Care Vaccine Effectiveness Group. Laniece Delaunay C, et al. JAMA Netw Open. 2024 Jul 1;7(7):e2419258. doi: 10.1001/jamanetworkopen.2024.19258. JAMA Netw Open. 2024. PMID: 38949812 Free PMC article.
Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.
Laniece Delaunay C, Melo A, Maurel M, Mazagatos C, Goerlitz L, O'Donnell J, Oroszi B, Sève N, Rodrigues AP, Martínez-Baz I, Meijer A, Mlinarić I, Latorre-Margalef N, Lazăr M, Pérez-Gimeno G, Dürrwald R, Bennett C, Túri G, Rameix-Welti MA, Guiomar R, Castilla J, Hooiveld M, Kurečić Filipović S, Samuelsson Hagey T, Dijkstra F, Borges V, Ramos Marín V, Bacci S, Kaczmarek M, Kissling E; European primary care VE group. Laniece Delaunay C, et al. Vaccine. 2024 Jul 25;42(19):3931-3937. doi: 10.1016/j.vaccine.2024.05.067. Epub 2024 Jun 4. Vaccine. 2024. PMID: 38839521 Free PMC article.
COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022.
Lanièce Delaunay C, Martínez-Baz I, Sève N, Domegan L, Mazagatos C, Buda S, Meijer A, Kislaya I, Pascu C, Carnahan A, Oroszi B, Ilić M, Maurel M, Melo A, Sandonis Martín V, Trobajo-Sanmartín C, Enouf V, McKenna A, Pérez-Gimeno G, Goerlitz L, de Lange M, Rodrigues AP, Lazar M, Latorre-Margalef N, Túri G, Castilla J, Falchi A, Bennett C, Gallardo V, Dürrwald R, Eggink D, Guiomar R, Popescu R, Riess M, Horváth JK, Casado I, García MDC, Hooiveld M, Machado A, Bacci S, Kaczmarek M, Kissling E; European Primary Care Vaccine Effectiveness Group. Lanièce Delaunay C, et al. Euro Surveill. 2024 Mar;29(13):2300403. doi: 10.2807/1560-7917.ES.2024.29.13.2300403. Euro Surveill. 2024. PMID: 38551095 Free PMC article.
Public health interventions, priority populations, and the impact of COVID-19 disruptions on hepatitis C elimination among people who have injected drugs in Montreal (Canada): A modeling study.
Lanièce Delaunay C, Klein MB, Godin A, Cox J, Kronfli N, Lebouché B, Doyle C, Maheu-Giroux M. Lanièce Delaunay C, et al. Int J Drug Policy. 2023 Jun;116:104026. doi: 10.1016/j.drugpo.2023.104026. Epub 2023 Apr 7. Int J Drug Policy. 2023. PMID: 37075626 Free PMC article.
Impacts of the COVID-19 pandemic on hepatitis C elimination in Canada: Where do we go from here?
Atif J, Udhesister STP, Abdelnabi MN, D'Souza S, Hung JH, Edgar RD, Gobran ST, Gomez-Escobar E, Greenwald ZR, Gallardo-Flores CE, Fontaine G, Jeong D, Lanièce-Delaunay C, Lawton D, Makuza JD, Masterman C, Marathe G, Mortazhejri S, Li J, Palmer M, Passos-Castilho AM, Sag M, Shengir M, Wallace HL, Mendlowitz AB; 2022–2023 trainees of the Canadian Network on Hepatitis C. Atif J, et al. Among authors: laniece delaunay c. Can Liver J. 2022 Nov 7;5(4):441-444. doi: 10.3138/canlivj-2022-0035. eCollection 2022 Nov. Can Liver J. 2022. PMID: 38144406 Free PMC article. No abstract available.
Impact of Hepatitis C Virus Cure on Depressive Symptoms in the Human Immunodeficiency Virus-Hepatitis C Virus Coinfected Population in Canada.
Marathe G, Moodie EEM, Brouillette MJ, Lanièce Delaunay C, Cox J, Martel-Laferrière V, Gill J, Cooper C, Pick N, Vachon ML, Walmsley S, Klein MB; Canadian Co-Infection Cohort. Marathe G, et al. Among authors: laniece delaunay c. Clin Infect Dis. 2023 Feb 8;76(3):e702-e709. doi: 10.1093/cid/ciac540. Clin Infect Dis. 2023. PMID: 35789253 Free PMC article.
Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C, Maheu-Giroux M, Marathe G, Saeed S, Martel-Laferrière V, Cooper CL, Walmsley S, Cox J, Wong A, Klein MB; Canadian Coinfection Cohort investigators. Lanièce Delaunay C, et al. Int J Drug Policy. 2022 May;103:103627. doi: 10.1016/j.drugpo.2022.103627. Epub 2022 Feb 24. Int J Drug Policy. 2022. PMID: 35218989 Free article.
16 results